MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 

2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions
View by Date

Monday, September 23, 2019

1:45pm-3:15pm
The Effectiveness of Rehabilitation Using Honda Walking Assist in Parkinson’s Disease Patients; The Gait Analysis by a Markerless Motion Capture System

N. Kawashima, M. Iijima, T. Hamano, K. Nagami, M. Isogai, M. Komachi, T. Furukado, A. Kumon, K. Miyashita, A. Sato, K. Hasegawa (Fujisawa, Japan)

Physical and Occupational Therapy  ·  Les Muses Terrace, Level 3
1:45pm-3:15pm
The effectiveness of two-weeks self-stretch based on post-isometric relaxation in Parkinson’s disease patients

A. Zimin, D. Yusupova (Moscow, Russian Federation)

Physical and Occupational Therapy  ·  Les Muses Terrace, Level 3
1:45pm-3:15pm
The Effects of Apomorphine infusion on Head ptosis, a case report

O. Skogar (Stockholm, Sweden)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3
1:45pm-3:15pm
The effects of exercise focused on ankle joint movement for postural instability in patients with Parkinson’s disease: A pilot study

R. Taniuchi, T. Harada, T. Makino, S. Togashi, K. Matsukawa, T. Hoshii (Otake, Japan)

Physical and Occupational Therapy  ·  Les Muses Terrace, Level 3
1:45pm-3:15pm
The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program

R. Pahwa, C. Tanner, L. Zhang, R. Johnson, C. Leroue, R. Patni (Kansas City, KS, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3
1:45pm-3:15pm
The evaluation of exosomes as a biomarker of Parkinson’s disease

Y. Ishiguro, T. Tsunemi, A. Yoroisaka, N. Hattori (Tokyo, Japan)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3
1:45pm-3:15pm
The First Chinese Case of Fragile X-associated Tremor/ Ataxia Syndrome :an underestimated disease in China

C. Zhao (Jinan, China)

Ataxia  ·  Les Muses, Level 3
1:45pm-3:15pm
The French NS-PARK/FCRIN network: a 5-year balance sheet

O. Rascol, JC. Corvol, F. Durif, E. Delappina, V. Chaigneau, JP. Azulay, P. Couratier, L. Defebvre, D. Devos, P. Damier, A. Doe, S. Drapier, S. Frismand, C. Geny, C. Giordana, JL. Houeto, P. Krystkowiak, E. Magnin, D. Maltete, W. Meissner, T. Moreau, E. Moro, P. Remy, C. Thiriez, S. Thobois, C. Tranchant, F. Viallet, M. Vidailhet (Paris, France)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3
1:45pm-3:15pm
The Frequency, Causes and Risk Factors of Discontinuation of Dopamine Agonists in Parkinson’s Disease Patients

N. Durmaz çelik, M. Kuzu Kumcu, S. Bostan, E. Yiğit Tekkanat, S. özkan (Eskisehir, Turkey)

Neuropharmacology  ·  Les Muses Terrace, Level 3
1:45pm-3:15pm
The Genetic Basis of paediatric movement disorders: experience from the SYNaPS Study

R. Maroofian, V. Salpietro, H. Houlden (London, United Kingdom)

Genetics  ·  Les Muses Terrace, Level 3